Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...